An American company that is looking to develop new drugs to improve sexual desire in women with low libido announced that it needs more time to bring the drug, flibanserin, on to the market after reaching an impasse with the Food and Drug Administration.
Since women's sexual issues are more psychological, than physical, Sprout Pharmaceuticals said that the drug works by acting on brain chemicals connected to mood and appetite, Fox News reported.
Despite of women suffering from hypoactive sexual desire disorder reporting boost in sexual desire and reduction in stress with the drugs, the FDA has twice rejected flibanserin since 2010.
Cindy Whitehead, Sprout's chief operating officer, said that there are now
24 drugs for men for either testosterone replacement or erectile dysfunction, yet there are zero drugs for the most common form of sexual dysfunction in women.
The US firm acquired flibanserin from a German drugmaker in 2011, after they abandoned development of the daily pill following an FDA rejection.